08:43 AM EDT, 10/16/2026 (MT Newswires) -- Pfizer (PFE.F) unit Pfizer Europe received a positive opinion from a European Medicines Agency committee on a proposed change in the indications of HER2-positive breast cancer drug Tukysa. The recommendation covers the use of Tukysa, in combination with trastuzumab and pertuzumab, for the maintenance treatment of adult patients with unresectable or metastatic HER2-positive breast cancer following first-line chemotherapy, according to a Friday note. Tukysa was previously approved, in combination with trastuzumab and capecitabine, for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens. The indication changes are subject to final approval from the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.